Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Tiziana Life Sciences Initiates Dosing in ALS Phase 2a Trial | WAPE

FilingSEC EDGAR6-K

Tiziana Life Sciences Initiates Dosing in ALS Phase 2a Trial

Sep 28, 2026, 07:00 ET · SEC accepted

StagePhase 2a

Filing content

Tiziana Life Sciences announced that the first participants have been dosed in its Phase 2a clinical trial of intranasal foralumab for ALS.

AI summary of the filing. Please also check the source.

Related companies

Tiziana Life Sciences LtdTLSAView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…